Hyperglycemia management in the hospital setting.

PURPOSE Recommendations for target blood glucose concentrations; factors that can complicate glycemic control; considerations that determine the aggressiveness of therapy to manage blood glucose levels; the role of oral antihyperglycemic drug therapy, sliding-scale insulin, continuous intravenous (i.v.) insulin infusions, and basal-bolus insulin therapy; the pharmacodynamics of various insulin products; computer decision support systems; and discharge planning for hospitalized patients with hyperglycemia are described. SUMMARY Target blood glucose concentrations depend on whether patients are critically ill or not. Factors that can complicate glycemic control include the severity of illness, medications, and inconsistent dietary intake. The expected course of treatment, anticipated length of stay, and preadmission glycemic control influence the aggressiveness of therapy to manage hyperglycemia. The usefulness of oral antihyperglycemic agents for managing in-hospital hyperglycemia is limited by difficulty titrating the dosage and promptly achieving target blood glucose concentrations. Sliding-scale insulin is not recommended because it is ineffective and potentially dangerous. Continuous i.v. insulin therapy or intermittent subcutaneous (s.c.) basal-bolus plus correction injections is preferred. Basal-bolus plus correction insulin therapy usually involves a single daily dose of insulin glargine at bedtime to prevent gluconeogenesis and ketogenesis, bolus injections of a rapid-acting insulin shortly before or after meals to meet prandial requirements, and correction bolus injections of rapid-acting insulin as needed for blood glucose elevations before or between meals. Hypoglycemia is the primary limiting factor for achieving optimal glycemic control with insulin therapy. Computer decision support systems can help reduce the risk of insulin infusion rate calculation errors and standardize insulin therapy. Communication with the primary care physician in the outpatient setting is an important part of discharge planning. CONCLUSION Sliding-scale insulin is not effective. Continuous i.v. insulin therapy or intermittent s.c. basal-bolus plus correction injections is preferred. Proactive management of hyperglycemia using these methods is needed to achieve and maintain glycemic control in hospitalized patients.

[1]  Bruce W Bode,et al.  Glucommander: a computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation. , 2005, Diabetes care.

[2]  M Schetz,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[3]  K. Jablonski,et al.  Unrecognized Diabetes Among Hospitalized Patients , 1998, Diabetes Care.

[4]  Kingston H. Tseng,et al.  Standards of Medical Care in Diabetes–2006 , 2006, Diabetes Care.

[5]  P. Brunetti,et al.  Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. , 2000, Diabetes.

[6]  James D Dziura,et al.  Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. , 2004, Diabetes care.

[7]  G. Grunkemeier,et al.  Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. , 2003, The Journal of thoracic and cardiovascular surgery.

[8]  G. Peterson Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir , 2006, Current medical research and opinion.

[9]  H. Mcdonald,et al.  Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. , 2005, JAMA.

[10]  S. Mudaliar,et al.  Insulin therapy in type 2 diabetes. , 2001, Endocrinology and metabolism clinics of North America.

[11]  M. Feinglos,et al.  Drug-induced hyperglycemia. , 2001, JAMA.

[12]  F. Brancati,et al.  Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. , 1997, Archives of internal medicine.

[13]  J. Plank,et al.  A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. , 2005, Diabetes care.

[14]  P. Dumo,et al.  Sliding-scale insulin: an antiquated approach to glycemic control in hospitalized patients. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[15]  Bruce W Bode,et al.  Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[16]  L. Heinemann,et al.  Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. , 2004, Diabetes.

[17]  Ace Ada Task Force on Inpatient Diabetes American College of Endocrinology and American Diabetes Association Consensus Statement on Inpatient Diabetes and Glycemic Control , 2006, Diabetes Care.

[18]  Irl B Hirsch,et al.  Management of diabetes and hyperglycemia in hospitals. , 2004, Diabetes care.

[19]  Silvio E. Inzucchi,et al.  Management of Hyperglycemia in the Hospital Setting , 2006 .